Undisclosed HER2 exon 20 insertion mutation inhibitor / Hanmi - LARVOL DELTA

Hanmi Pharmaceutical announced on the 29th that it had presented…research results as posters on…selective HER2 exon 20 insertion mutation inhibitor, and SOS1 inhibitor (HM99462) at the ’EORTC-NCI-AACR 2024’ international cancer conference…[Google Translation] (Hanmi Press Release) - "Hanmi's selective HER2 inhibitor minimizes side effects by increasing selectivity for wild-type EGFR (epidermal growth factor receptor), and exhibits anticancer activity in animal models of HER2 exon 20 insertion mutations and HER2 wild-type tumors through oral administration...Hanmi Pharmaceutical demonstrated the efficacy of inhibiting brain metastasis by confirming a decrease in the level of brain metastasis compared to the control group...HM99462 exhibited anticancer activity in various KRAS mutant solid cancer cell lines, including KRAS G12C as well as G12D/V/S, and G13D, by inhibiting the protein binding between KRAS-SOS1 regardless of KRAS mutation...it demonstrated a strong synergistic effect through vertical inhibition with EGFR mutation inhibitors, and confirmed the possibility of treating EGFR mutant lung cancer. Hanmi Pharmaceutical plans to apply for an investigational new drug (IND) plan to enter phase 1 clinical trials in the first half of next year."

New P1 trial • Preclinical • Lung Cancer • Oncology • Solid Tumor